The jury is still out on what 2019 will bring for investors. Despite an encouraging start to the year, investors are worried that earnings season may reveal share prices are still overvalued.
However, even in these uncertain times, there are still compelling growth stocks to be found. You just have to know where to look. Here we turned to TipRanks’ Stock Screener to pinpoint the best growth stocks out there right now. These are stocks with a strong outlook for the year ahead.
TipRanks uses a natural language processing algorithm to rank analysts based on their success rate and average return. That allows us to filter for growth stocks with a ‘strong buy’ consensus from only the top-performing analysts who consistently outperform the market.
Let’s take a closer look at their five favorite growth stocks for 2019 now:
Cloud communications platform Twilio had a killer 2018. Accelerating revenue growth and improving profitability, coupled with multiple expansion, contributed to TWLO shares more than tripling last year.
What’s interesting is that even after this tremendous run, the stock remains a stellar bet for 2019. Indeed, TWLO boasts only buy ratings from the Street right now. That’s with 11 consecutive buy ratings from top analysts over the last three months. Their average price target stands at $102.
One of these analysts is KeyBanc’s Brent Bracelin (Track Record & Ratings). According to TipRanks, this is a top 10 analyst out of over 5,000 tracked analysts (and the number 1 analyst for 2018).
“We see multiple upside levers to consensus growth of 31 percent in 2019 vs. 68 percent last quarter and are raising our estimates and PT to $114 from $103” he wrote in a January 7 report. These potential growth drivers include new products; improving sales productivity; and higher usage and pricing.
And while further multiple expansion is less likely in 2019, Bracelin believes growth fundamentals remain strong and could warrant additional price appreciation.
It’s also worth bearing in mind the recent $2 billion acquisition of API-centric email platform SendGrid. “Our scenario analysis of the SendGrid acquisition suggests that base-case revenue could exceed $1B next year and then triple to $3B within five years” says Bracelin.
Athletics apparel retailer Lululemon is buzzing right now. Shares surged after LULU provided an update on its performance over the 2018 Holiday period demonstrating continued robust top-line momentum.
Susquehanna’s Sam Poser (Track Record & Ratings) has a Street-price target on LULU of $195. From current levels that translates into sizable upside potential of more than 30 percent. “Perhaps more than any other retailer, LULU knows who they are, why they exist, and commits to their purpose” Poser wrote in a January 7 report.
LULU has stuck close to its comfort and performance DNA and will continue to reap the benefit of being one of the most authentic brands in the eyes of the consumer, says the analyst.
He concludes: “Exceptional execution, best-in-class customer engagement, and innovative product is driving top-tier results which we anticipate will continue through the balance of FY18 and into at least FY19.”
Notably, top-rated Buckingham analyst Eric Tracy (Track Record & Ratings) has also just upgraded LULU from ‘hold’ to ‘buy’ while boosting his price target to $157 from $151. Tracy made the move on January 9, citing a “superior” fundamental algorithm that’s supportive of a premium valuation.
Thirteen top-performing analysts have published recent LULU buy ratings, with only two analysts rating the stock a ‘hold’. Their average price target stands at $167.
Cloud stock MongoDB calls itself the ‘most popular database for modern apps.’
Oppenheimer’s Ittai Kidron (Track Record & Ratings) highlights Mongo one of his top picks for 2019. The analyst, who is ranked No. 13 out of over 5,000 analysts tracked by TipRanks, reiterated his MDB buy rating on January 7. That’s with a $90 price target for 22 percent upside potential.
Analysts have stuck to their bullish thesis after Amazon’s AWS unveiled a new cloud database called DocumentDB that emulates API functionality similar to MongoDB.
While calling AWS’ competitive move ‘undoubtedly a negative development’, Oppenheimer’s Kidron says he has more questions that answers at this time. As a result, the analyst remains ‘comfortable’ with the MDB story.
Kidron reminds investors, “MongoDB has executed well in the face of such competition, illustrated by its committed user base, excellent brand, and strong growth.”
Similarly, KeyBanc’s Brent Bracelin (Track Record & Ratings) wrote on January 9, “We remain bullish on the prospects for MDB to sustain high growth.” He sees ample room for MongoDB to compete and win its fair share within one of the largest TAMs within software.
Indeed, the database market represents one of the largest categories of software that could grow into a $63B TAM by 2020 vs. $44B in 2016. Plus multi-cloud and new functionalities only available in MDB’s latest version release represent ‘key differentiators’ that help mitigate the potential threat of AWS’s new offering.
What also stands out is that Mongo has scored only buy ratings from top analysts in the last three months. These top analysts see the stock spiking 28 percent from current levels.
Five-star JP Morgan analyst Doug Anmuth (Track Record & Ratings) picks e-commerce giant Amazon as one of his best ideas for 2019. He calls the valuation ‘compelling’ and predicts a revenue re-acceleration in Q1 2019.
That’s with Amazon Web Services and advertising driving 80 basis points of operating margin expansion to 6 percent this year. As a result, Anmuth reiterated his buy rating and $2,100 price target on January 9.
Even though AMZN is already one of the world’s largest retailers, with one of the world’s largest software businesses, its potential for growth is still significant.
“Amazon is massive, but small in context of the commercial opportunity the company is pursuing” says top-rated Pivotal Research analyst Brian Wieser (Track Record & Ratings). He has just initiated coverage of the stock on January 7 with a buy rating and $1,920 price target.
“With a focus on selling as many consumer goods as possible and much success in attempting to do so, we see Amazon’s retail activities as a play on global consumer spending” the analyst explained.
He points to a recent Euromonitor estimate of global consumer spending as equaling $45 trillion in 2018- and believes this is the figure investors should be looking at. “Given Amazon’s ambitions and its demonstrated abilities, we think this is a reasonable TAM (total addressable market) to consider.”
From this Wieser calculates that AMZN is currently only covering an approximate 1 percent share of its TAM potential.
In total, AMZN scores an extremely impressive 34 buy ratings from top analysts over the last three months vs only 2 hold ratings. The $2,140 average price target suggests shares can surge 34 percent from current levels.
Last but not least we have healthcare stock Sarepta Therapeutics. Sarepta is a biopharma focused on precision genetic medicines to treat rare neuromuscular diseases.
So far the company has one drug on the market, Exondys 51, for the treatment of Duchenne muscular dystrophy (DMD). This is a genetic disorder characterized by progressive muscle degeneration and weakness.
“Based on strong Exondys 51 uptake, positive US sales guidance, and potentially transformative gene therapies clinical development that could reach a substantially larger proportion of the DMD population, we rate Sarepta Outperform” wrote RBC Capital’s Brian Abrahams (Track Record & Ratings).
He has a buy rating on Sarepta with a $175 price target. Right now the stock is trading at $119, following a 93 percent growth spirt in the last year. However, in the last three months Sarepta has experienced a slight pullback of 10 percent.
Abrahams calls this weakness ‘unfounded’ and, in a January 7 report, recommends buying the shares. He believes the market misunderstood an investor presentation on SPRT’s limb girdle muscular dystrophy (LGMD) data and on the regulatory/ manufacturing path for microdystrophin gene therapy.
“Following our discussion/clarifications with the company, we believe timelines and prospects for both remain intact and we remain bullish on both programs” the RBC analyst told investors.
The rest of the Street agrees. The stock has 100 percent Street support right now, with 11 consecutive buy ratings from top analysts. These analysts, on average, see shares rising 64 percent to $197.